trending Market Intelligence /marketintelligence/en/news-insights/trending/sxf17IaM-tQZxfOrPO31Jw2 content
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

US clears Roche's $4.3B takeover of Spark Therapeutics

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

US clears Roche's $4.3B takeover of Spark Therapeutics

Roche Holding AG's acquisition of Spark Therapeutics Inc. received approval in the U.S. after months of delays.

In line with the U.K. Competition and Markets Authority's decision earlier in the day, the U.S. Federal Trade Commission granted the $4.3 billion deal unconditional clearance and termination of the waiting period under the Hart-Scott-Rodino Act.

The transaction has now received all required antitrust approvals.

Swiss drugmaker Roche launched a buyout offer to acquire all outstanding shares of the Philadelphia-based gene-therapy maker for $114.50 apiece in March. Due to investigations by Britain's antitrust regulator and the FTC, the offer was extended 10 times.

The offer was set to expire at 5 p.m. ET on Dec. 16.

The closing of the tender offer is subject to customary closing conditions.

MacKenzie Partners Inc. is the information agent for the tender offer.